Literature DB >> 16482632

Correlation between Saccharomyces cerevisiae DNA in intestinal mucosal samples and anti-Saccharomyces cerevisiae antibodies in serum of patients with IBD.

R-C Mallant-Hent1, M Mooij, B-Me von Blomberg, R-K Linskens, A-A van Bodegraven, P-Hm Savelkoul.   

Abstract

AIM: To investigate the correlation between ASCA and presence of mucosal S. cerevisiae DNA in a population of CD, ulcerative colitis (UC) patients and controls.
METHODS: S. cerevisiae-specific primers and a fluorescent probe were designed for a 5' exonuclease real time PCR (TaqMan) assay, which is a homogenous system using a fluorescent-labelled probe for the detection of PCR product in real time. We analyzed the relation of the PCR results with the ASCA findings in a group of 76 inflammatory bowel disease (IBD) patients (31 CD, 45 UC) and 22 healthy controls (HC).
RESULTS: ASCA (IgA or IgG) were positive in 19 (61%) patients with CD, 12 (27%) with UC and none of the HC. PCR amplification was inhibited and excluded from the final results in 10 (22%) UC patients, 7 (22%) CD patients, and 6 (30%) HC. In only 15 of the mucosal samples, S. cerevisiae DNA was detected by real time PCR, including 7 (29%) in CD, 7 (19%) in UC, 1 (6%) in HC. In 4 CD and in 4 UC patients, ASCA and mucosal S. cerevisiae were positive. Mucosal S. cerevisiae was present in combination with negative ASCA IgA and IgG in 3 UC, and 3 CD patients.
CONCLUSION: We conclude that since the presence of S. cerevisiae in colonic mucosal biopsy specimens is very rare, ASCA is unlikely to be explained by continuous exposure to S. cerevisiae in the mucosa. Therefore, ASCA formation must occur earlier in life and levels remain relatively stable thereafter in immunological susceptible persons.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16482632      PMCID: PMC4066041          DOI: 10.3748/wjg.v12.i2.292

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

1.  Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.

Authors:  M Peeters; S Joossens; S Vermeire; R Vlietinck; X Bossuyt; P Rutgeerts
Journal:  Am J Gastroenterol       Date:  2001-03       Impact factor: 10.864

2.  Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease.

Authors:  C L Sutton; H Yang; Z Li; J I Rotter; S R Targan; J Braun
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

3.  Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families.

Authors:  S Vermeire; M Peeters; R Vlietinck; S Joossens; E Den Hond; V Bulteel; X Bossuyt; B Geypens; P Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2001-02       Impact factor: 5.325

4.  Intestinal permeability in Crohn's disease patients and their first degree relatives.

Authors:  M Secondulfo; L de Magistris; R Fiandra; L Caserta; M Belletta; M T Tartaglione; G Riegler; F Biagi; G R Corazza; R Carratù
Journal:  Dig Liver Dis       Date:  2001-11       Impact factor: 4.088

5.  Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil cytoplasmic antibodies in coeliac disease before and after gluten-free diet.

Authors:  A Granito; D Zauli; P Muratori; L Muratori; A Grassi; R Bortolotti; N Petrolini; L Veronesi; P Gionchetti; F B Bianchi; U Volta
Journal:  Aliment Pharmacol Ther       Date:  2005-04-01       Impact factor: 8.171

6.  Saccharomyces: is it a probiotic or a pathogen and what is the significance of an elevated anti-S. cerevisiae antibody?

Authors:  Martin H Floch
Journal:  J Clin Gastroenterol       Date:  2003-01       Impact factor: 3.062

7.  Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; I A Mouzas; I G Vlachonikolis; E Anagnostopoulou; E Castanas; A N Maniatis; E A Kouroumalis
Journal:  Am J Gastroenterol       Date:  2001-02       Impact factor: 10.864

8.  Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study.

Authors:  F Seibold; O Stich; R Hufnagl; S Kamil; M Scheurlen
Journal:  Scand J Gastroenterol       Date:  2001-02       Impact factor: 2.423

9.  Familial expression of anti-Saccharomyces cerevisiae Mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study.

Authors:  V Annese; A Andreoli; A Andriulli; R Dinca; P Gionchetti; A Latiano; G Lombardi; A Piepoli; D Poulain; B Sendid; J F Colombel
Journal:  Am J Gastroenterol       Date:  2001-08       Impact factor: 10.864

10.  Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods.

Authors:  Ronald K Linskens; Rosalie C Mallant-Hent; Z M Anthonie Groothuismink; Liesbeth E Bakker-Jonges; Joop P van de Merwe; Herbert Hooijkaas; B Mary E von Blomberg; Stephan G M Meuwissen
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-09       Impact factor: 2.566

View more
  5 in total

1.  Distinct patterns of IgG and IgA against food and microbial antigens in serum and feces of patients with inflammatory bowel diseases.

Authors:  Lisa Frehn; Anke Jansen; Eveline Bennek; Ana D Mandic; Ilknur Temizel; Stefanie Tischendorf; Julien Verdier; Frank Tacke; Konrad Streetz; Christian Trautwein; Gernot Sellge
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

Review 2.  Biomarkers of inflammatory bowel disease.

Authors:  Yi Fengming; Wu Jianbing
Journal:  Dis Markers       Date:  2014-05-19       Impact factor: 3.434

3.  The Correlation of Serum IL-12B Expression With Disease Activity in Patients With Inflammatory Bowel Disease.

Authors:  Hye Won Lee; Sook Hee Chung; Chang Mo Moon; Xiumei Che; Seung Won Kim; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

4.  First-degree Relatives of Celiac Disease Patients Have Increased Seroreactivity to Serum Microbial Markers.

Authors:  Liisa Viitasalo; Sari Iltanen; Heini Huhtala; Päivi Saavalainen; Katri Kaukinen; Katri Lindfors; Kalle Kurppa
Journal:  Nutrients       Date:  2020-04-13       Impact factor: 5.717

5.  Remission in Crohn's disease is accompanied by alterations in the gut microbiota and mucins production.

Authors:  Daniéla Oliveira Magro; Andrey Santos; Dioze Guadagnini; Flavia Moreira de Godoy; Sylvia Helena Monteiro Silva; Wilson José Fernandes Lemos; Nicola Vitulo; Sandra Torriani; Lilian Vital Pinheiro; Carlos Augusto Real Martinez; Mario José Abdalla Saad; Claudio Saddy Rodrigues Coy
Journal:  Sci Rep       Date:  2019-09-13       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.